SCHEMBL335085

SCHEMBL335085

CCN(CC)C(=O)COc1ccc(C(C)NCCN)cc1

nearest known ligand 0.53

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 1/20 0.51
RAB9A P51151 1/20 0.51
TRPM8 Q7Z2W7 4/20 0.48
BCHE P06276 1/20 0.46
ACHE P22303 1/20 0.46
MEN1 O00255 2/20 0.43
KMT2A Q03164 2/20 0.43
ACACB O00763 5/20 0.42
LMNA P02545 1/20 0.41
ALDH1A1 P00352 2/20 0.41
TSHR P16473 2/20 0.41
ACACA Q13085 1/20 0.41
KDM4E B2RXH2 1/20 0.41
POLB P06746 1/20 0.41
MAPT P10636 1/20 0.41
L3MBTL1 Q9Y468 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL335399 0.87 SMN1; SMN2 (0.49) RAB9AACACBLMNAALDH1A1TSHR
SCHEMBL10244841 0.84 TRPM8 (0.48) NPC1RAB9ATRPM8BCHEACHE
SCHEMBL4633972 0.76 NPC1 (0.62) NPC1RAB9ATRPM8BCHEACHE
SCHEMBL335329 0.76 ALDH1A1 (0.56) NPC1RAB9ABCHEACHEKMT2A
SCHEMBL10436867 0.74 NPC1 (0.60) NPC1RAB9ATRPM8LMNAALDH1A1
SCHEMBL334936 0.73 FKBP1A (0.69) NPC1RAB9AMEN1KMT2ALMNA
SCHEMBL18575578 0.72 HTR1A (0.50) MEN1KMT2ALMNAALDH1A1MAPT
SCHEMBL18575437 0.72 PKM (0.57) ACHEMEN1KMT2AACACBLMNA
SCHEMBL10243759 0.72 SMN1; SMN2 (0.46) RAB9ATRPM8ACACBALDH1A1TSHR
SCHEMBL2007436 0.72 RAB9A (0.60) NPC1RAB9ATRPM8MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8097708-B2 10a-Azalide compound TAISHO PHARMACEUTICAL CO., LTD. (JP) 2012-01-17 US disclosed
US-20090281292-A1 10a-Azalide Compound MEIJI SEIKA PHARMA CO., LTD. (JP) 2009-11-12 US disclosed
EP-1985620-A1 10a-AZALIDE COMPOUND TAISHO PHARMACEUTICAL CO., LTD (JP) 2008-10-29 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090281292-A1 10a-Azalide Compound IL17A, AZI2, HDAC9 NPC1 209/4885RAB9A 5/4885TRPM8 4534/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.